• Cellvizio®
    • Overview
    • Education
    • Economics
  • Indications
    • Gastroenterology
      • Barrett’s Esophagus
      • Pancreatic Cysts
      • Gastric Disease
      • Inflammatory Bowel Diseases
      • Irritable Bowel Syndrome – Food Intolerance
      • Bilio-Pancreatic Strictures
      • Colorectal Lesions
    • Pulmonology
      • Lung Nodules
      • Lung Transplant
    • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
CellTolerance®: A Breakthrough in Food Intolerance Diagnosis

CellTolerance®: A Breakthrough in Food Intolerance Diagnosis

by Elizabeth | Mar 10, 2026 | Press Coverage

This piece co-authored by Linda Nguyen, MD, FACG, AGAF and Daryl Donatelli, MBA in Medical Device News Magazine discusses how CellTolerance is transforming the patient experience in digestive health, moving from “dealing with symptoms” to...
Mauna Kea Technologies Accelerates International Expansion with New Regulatory Clearances in Switzerland and the United Kingdom 

Mauna Kea Technologies Accelerates International Expansion with New Regulatory Clearances in Switzerland and the United Kingdom 

by Elizabeth | Feb 23, 2026 | News

These clearances enable the commercialization of Cellvizio® in two major markets and accelerate the Group’s international expansion  First order for the next-generation Cellvizio® (Gen 3) platform received from Bern University Hospital, dedicated to functional...
BFM Business – Value Added: They Like Mauna Kea Technologies – 02/16

BFM Business – Value Added: They Like Mauna Kea Technologies – 02/16

by Elizabeth | Feb 17, 2026 | Press Coverage, Press Coverage

Mathias Pecqueur, French Small Caps Manager and President of Maitice Gestion, discussed Mauna Kea Technologies on the program BFM Bourse, hosted by Guillaume Sommerer. See the full clip here
Mauna Kea Technologies Announces New Commercial Organization to Accelerate Growth Outside the United States

Mauna Kea Technologies Announces New Commercial Organization to Accelerate Growth Outside the United States

by Elizabeth | Feb 4, 2026 | News

Building on Strong 2025 Momentum with Accelerated Sales Growth in Pancreatic Cysts & €1M Milestone for CellTolerance® Appointment of Benoit Chardon as Fractional Chief Commercial Officer to Lead Global Scale-Up of CellTolerance® Outside the United States...
United European Gastroenterology (UEG) Week 2026 Barcelona, Spain

United European Gastroenterology (UEG) Week 2026 Barcelona, Spain

by Elizabeth | Jan 29, 2026 | Events

United European Gastroenterology (UEG) Week is the largest and most prestigious GI meeting in Europe. It combines world class scientific research, invited lectures by leading minds in gastroenterology and an excellent Postgraduate Teaching Programme....
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026
  • Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying “Triple Healing”, a Cellvizio®— Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis
  • Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation
  • Mauna Kea Technologies Announces Nomination of 3 New Directors
  • Publication of the 2025 Annual Financial Report 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Cookie policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}